Hikma Pharmaceuticals acquiring Baxter International's U.S. generic injectables business for approximately $112M in cash

Baxter International Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Hikma Pharmaceuticals plc

U.K. / Small-Cap Biopharma (<$1 billion)

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced